These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33096421)

  • 1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
    Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
    Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
    Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
    Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
    Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
    Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
    Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
    Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
    Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
    Fernández-Teruel C; Fudio S; Lubomirov R
    Cancer Chemother Pharmacol; 2022 May; 89(5):585-594. PubMed ID: 34739582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
    Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
    Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
    Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T
    Intern Med J; 2024 Jul; 54(7):1087-1096. PubMed ID: 38369719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurbinectedin in the treatment of relapsed small cell lung cancer.
    Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
    Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
    Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
    Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
    Rittberg R; Leung B; Al-Hashami Z; Ho C
    Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
    Shinn LT; Vo KA; Reeves DJ
    Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
    Cheng Y; Wu C; Wu L; Zhao J; Zhao Y; Chen L; Xin Y; Zhang L; Pan P; Li X; Li J; Dong X; Tang K; Gao E; Yu F
    Sci Rep; 2024 Feb; 14(1):3598. PubMed ID: 38351146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
    Singh S; Jaigirdar AA; Mulkey F; Cheng J; Hamed SS; Li Y; Liu J; Zhao H; Goheer A; Helms WS; Wang X; Agarwal R; Pragani R; Korsah K; Tang S; Leighton J; Rahman A; Beaver JA; Pazdur R; Theoret MR; Singh H
    Clin Cancer Res; 2021 May; 27(9):2378-2382. PubMed ID: 33288660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
    Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
    J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
    Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
    Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
    Desai A; Smith CJ; Ashara Y; Orme JJ; Zanwar S; Potter A; Hocum C; Moffett JN; Schwecke AJ; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Molina J; Dimou A; Mansfield AS; Parikh K; Leventakos K
    Clin Lung Cancer; 2023 Dec; 24(8):689-695.e1. PubMed ID: 37880074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.